Literature DB >> 22876946

Synthesis and biological activity of 3-N-substituted estrogen derivatives as breast cancer agents.

Zhongliang Wan1, Musiliyu A Musa, Patrick Joseph, John S Cooperwood.   

Abstract

3-N-substituted-estrogen derivatives were synthesized and characterized. Their antiproliferative activities against human ER (+) MCF-7 (Breast), ER (-) MDA-MB-231 (breast) and Ishikawa (endometrial) cancer cell lines were determined after 72 hours drug exposure employing CellTiter-Glo assay at concentrations ranging from (0.01-100,000 nM). The antiproliferative activities of these compounds were compared to tamoxifen (TAM), 4-hydroxytamoxifen (4-OHT, active metabolite of tamoxifen) and raloxifene (RAL). In vitro results indicated that compound 5 (IC50 = 12 µM) displayed comparable antiproliferative activity against MDA-MB 231 cell line; while compounds 6, 7 and 13 (IC50 = 12 µM) displayed higher activity against MCF-7 and Ishikawa cell lines, in comparison to TAM activity (19-33 µM).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22876946      PMCID: PMC3756546          DOI: 10.2174/1389557511313090012

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  43 in total

1.  Cloning of a novel receptor expressed in rat prostate and ovary.

Authors:  G G Kuiper; E Enmark; M Pelto-Huikko; S Nilsson; J A Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

Review 2.  Interdependence of oestrogen and insulin-like growth factor-I in the brain: potential for analysing neuroprotective mechanisms.

Authors:  Pablo Mendez; Iñigo Azcoitia; Luis Miguel Garcia-Segura
Journal:  J Endocrinol       Date:  2005-04       Impact factor: 4.286

Review 3.  Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture.

Authors:  L J Lerner; V C Jordan
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

4.  Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1998-05-16       Impact factor: 79.321

Review 5.  The role of tamoxifen in the treatment and prevention of breast cancer.

Authors:  V C Jordan
Journal:  Curr Probl Cancer       Date:  1992 May-Jun       Impact factor: 3.187

6.  Importance of the alkylaminoethoxy side-chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus.

Authors:  V C Jordan; B Gosden
Journal:  Mol Cell Endocrinol       Date:  1982-08       Impact factor: 4.102

Review 7.  Role of hormones in mammary cancer initiation and progression.

Authors:  I H Russo; J Russo
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

8.  The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity.

Authors:  S P Crouch; R Kozlowski; K J Slater; J Fletcher
Journal:  J Immunol Methods       Date:  1993-03-15       Impact factor: 2.303

9.  Syntheses and affinities of novel organometallic-labeled estradiol derivatives: a structure-affinity relationship.

Authors:  H el Amouri; A Vessières; D Vichard; S Top; M Gruselle; G Jaouen
Journal:  J Med Chem       Date:  1992-08-21       Impact factor: 7.446

Review 10.  Aromatase inhibitors as adjuvant therapies in patients with breast cancer.

Authors:  R Charles Coombes; L Gibson; E Hall; M Emson; J Bliss
Journal:  J Steroid Biochem Mol Biol       Date:  2003-09       Impact factor: 4.292

View more
  3 in total

1.  In-vitro Antiproliferative Activity of New Tetrahydroisoquinolines (THIQs) on Ishikawa Cells and their 3D Pharmacophore Models.

Authors:  Suresh Kumar V K Eyunni; Madhavi Gangapuram; Kinfe K Redda
Journal:  Lett Drug Des Discov       Date:  2014       Impact factor: 1.150

Review 2.  Antimitotic drugs in the treatment of cancer.

Authors:  Rustelle Janse van Vuuren; Michelle H Visagie; Anne E Theron; Annie M Joubert
Journal:  Cancer Chemother Pharmacol       Date:  2015-11-12       Impact factor: 3.333

3.  Evaluating the potential bioactivity of a novel compound ER1626.

Authors:  Lijun Wang; Yanyan Zeng; Tianling Wang; Hongyi Liu; Hong Xiao; Hua Xiang
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.